SUMMARY We measured the cerebral blood flow (CBF) of 16 patients by the xenon-133 intracarotid method before and after the intramuscular injection of ergotamine tartrate. The regional and hemispheric CBF was unaltered, even in 3 migraneurs in whom ergotamine relieved the headache. Ergotamine tartrate in therapeutic doses has no effect on the cerebral circulation.
EVIDENCE for an ergotamine effect on the cerebral circulation is indirect and contradictory; therefore, we measured cerebral blood flow (CBF) directly, before and after the administration of therapeutic doses of ergotamine tartrate. 
Methods
Regional cerebral blood flow (rCBF) studies 1 were carried out prior to clinically indicated carotid arteriography in 16 patients. Their age, sex and diagnosis are listed in the table. Although cases 5, 6, 8, 10 and 11 were investigated because of suspected brain disease, no brain lesions were demonstrated; hence these patients were, in effect, non-migranous controls. Informed consent was obtained in all cases. Three millicuries of xenon-133 were injected through an indwelling catheter into the internal carotid artery. The intracarotid catheter was also used for mean arterial blood pressure (MABP) measurements and arterial blood gases analysis. The clearance rate of the isotope, and hence the rCBF, was measured by 16 extra- 
Results
Ergotamine tartrate did not change the focal cerebral blood flow in any of the patients. Three migraneurs received the drug during the headache phase with relief of pain, but no change in rCBF. 3 The mean hemispheric CBF value showed a slight rise after ergotamine tartrate injection, but this rise was not statistically significant (table).
Discussion
Observations of the effect of ergotamine on cerebrospinal fluid pulsatility, 4 retinal vessels, 5 ' 6 and carotid angiograms, 7 as reflections of CBF, have been equivocal. Lennox et al. 8 reported that ergotamine increased CBF; however, their data were obtained from thermoelectric flowmeter studies of the internal jugular vein, an indirect and unreliable way of estimating CBF. Shenkin, 9 by using the nitrous oxide method, found reduced CBF after ergotamine; but his high control values for CBF and his failure to note Paco 2 suggest that these data, too, may be unreliable. Using the more reliable intracarotid xenon-133 method, Simard and Paulson 10 demonstrated that 1 mg of ergotamine, given intravenously, had no effect on rCBF during a prolonged migranous aura, nor 3 months later, when the patient was asymptomatic. The present study suggests, further, that ergotamine tartrate in therapeutic doses has no effect on CBF during the symptomatic headache phase of migraneurs, nor on the cerebral circulation of non-migraneurs.
Since we did not measure rCBF in the vertebrobasilar circuit, we cannot rule out an effect of ergotamine on this area of blood flow.
